Despite experiencing significant reductions in triglycerides, patients with triglycerides over 150 mg/dL and a high risk of ...

Despite experiencing significant reductions in triglycerides, patients with triglycerides over 150 mg/dL and a high risk of ...

The lack of effect on different measures of coronary plaque reinforce the need for a large CV outcomes trial in these ...

In a major new study, researchers from Intermountain Health in Salt Lake City have found that weight loss drugs used by patients who have high triglycerides do not increase their risk of pancreatitis ...

In a major new study, researchers from Intermountain Health in Salt Lake City have found that weight loss drugs used by patients who have high triglycerides do not increase their risk of pancreatitis ...

On Wednesday, Ionis Pharmaceuticals Inc. IONS said it is cutting the annual list price of its triglyceride-lowering drug ...

Millions of Americans take statins to lower their cholesterol, but many still have dangerously high levels of triglycerides and other blood fats that statins don’t address. Now, an experimental pill ...

Ionis Pharma projects $2B+ peak revenue for Olezarsen, which is highly conservative given the U.S. addressable market. Read ...

An imaging sub-study of the ASO in hypertriglyceridemia patients presented at ACC highlights uncertainty about the drug's impact on cardiac outcomes.

Treatment for coronary artery disease (CAD) involves lifestyle changes alongside medications such as antiplatelets and statins. There are many different medications to treat CAD. Treatment for CAD is ...

In a major new study, researchers from Intermountain Health in Salt Lake City have found that weight loss drugs used by patients who have high triglycerides do not increase their risk of pancreatitis ...